Market closedNon-fractional

Voyager Therapeutics/VYGR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Voyager Therapeutics

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Ticker

VYGR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Lexington, United States

Employees

162

VYGR Metrics

BasicAdvanced
$420M
Market cap
-
P/E ratio
-$0.06
EPS
1.04
Beta
-
Dividend rate
$420M
1.04
5.639
5.555
12.319
14.062
-2.65%
-1.09%
3.061
1.24
1.24
44.262
-37.58%
-102.57%
-9.30%
-60.45%

What the Analysts think about VYGR

Analyst Ratings

Majority rating from 10 analysts.
Buy

VYGR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-57.94% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-78.33%
Net income
-$11M
-120.07%
Profit margin
-57.94%
-192.63%

VYGR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 54.55%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.51
-$0.59
$1.25
-$0.20
-
Expected
-$0.57
-$0.58
-$0.29
-$0.44
-$0.41
Surprise
-10.30%
1.50%
-533.17%
-54.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Voyager Therapeutics stock?

Voyager Therapeutics (VYGR) has a market cap of $420M as of July 06, 2024.

What is the P/E ratio for Voyager Therapeutics stock?

The price to earnings (P/E) ratio for Voyager Therapeutics (VYGR) stock is 0 as of July 06, 2024.

Does Voyager Therapeutics stock pay dividends?

No, Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Voyager Therapeutics dividend payment date?

Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders.

What is the beta indicator for Voyager Therapeutics?

Voyager Therapeutics (VYGR) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Voyager Therapeutics stock

Buy or sell Voyager Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing